Market Place
Sourcing Support
NS Pharma Announces Change in Commercial Leadership
26 Nov 2024 //
PR NEWSWIRE
NS Pharma`s Galactic53 Trial Data Is Published in Scientific Reports
15 Oct 2024 //
PR NEWSWIRE
Dr. Wouter Latour Joins PharmaJet as Chief Executive Officer
02 Oct 2024 //
BUSINESSWIRE
NS-050/NCNP-03 Gets FDA Rare Pediatric Disease Designation
10 Sep 2024 //
PR NEWSWIRE
NS Pharma Names New President For Orphan Drug Development
10 Jul 2024 //
PR NEWSWIRE
NS Pharma`s Duchenne drug Viltepso flunks confirmatory trial
29 May 2024 //
FIERCE PHARMA
Ns Pharma Viltolarsen Phase 3: Racer53 Preliminary Results Shared
27 May 2024 //
PR NEWSWIRE
NS Pharma Announces Research Alliance with MiNA Therapeutics
04 Apr 2024 //
PR NEWSWIRE
Japan`s NS Pharma & UK-based MiNA Therapeutics lay focus on rare diseases
04 Apr 2024 //
BIOSPECTRUM ASIA
NS Pharma, Inc. Shares New VILTEPSO® (Viltolarsen) Data at the MDA Conference
06 Mar 2024 //
PR NEWSWIRE
The European Commission Grants Orphan Drug Designation to NS-229
22 Jan 2024 //
PR NEWSWIRE
NS-089/NCNP-02 Receives ODD from EC for Duchenne Muscular Dystrophy
21 Dec 2023 //
PR NEWSWIRE
NS-089/NCNP-02 Preclinical Data Published in Molecular Therapy Nucleic Acids
17 Oct 2023 //
PR NEWSWIRE
NS-018, Treatment for Myelofibrosis, Receives Orphan Drug Designation
08 Aug 2023 //
PR NEWSWIRE
FDA Grants Orphan Drug Designation to NS-089/NCNP-02
07 Aug 2023 //
PR NEWSWIRE
NS Pharma Announces FDA Clearance to Initiate a PhI/II Study for NS-050/NCNP-03
15 Jun 2023 //
PR NEWSWIRE
VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data Published
09 May 2023 //
PR NEWSWIRE
NS Pharma Announces FDA Clearance to Initiate Phase II Study for NS-089/NCNP-02
14 Apr 2023 //
PR NEWSWIRE
VILTEPSO injection Open Label Extension Trial Data Scheduled for Presentation
19 Mar 2023 //
PR NEWSWIRE
NS Pharma Announces First Patient Enrolled in PII to Assess Safety of NS-018
17 Feb 2023 //
PR NEWSWIRE
NS Pharma opens new U.S drug discovery center in Cambridge, MA
06 Jan 2023 //
PR NEWSWIRE
NS Pharma Announces Receipt of ODD from the U.S. FDA for NS-018
20 Dec 2022 //
PR NEWSWIRE
NS Pharma Reports on Results of VILTEPSO injection
24 Oct 2022 //
PRNEWSWIRE
VILTEPSO (viltolarsen) injection Four-Year Clinical Trial Data
04 Oct 2022 //
PRNEWSWIRE
VILTEPSO injection Four-Year Trial Data to be Presented at World Muscle Society
04 Oct 2022 //
PRNEWSWIRE
VILTEPSO (viltolarsen) injection: Long-Term Efficacy and Safety Data
31 May 2022 //
PRNEWSWIRE
VILTEPSO Interim Long-Term Clinical Trial Data Scheduled for Presentation
17 Sep 2021 //
PRNEWSWIRE
VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Presented
01 Jul 2021 //
PR NEWSWIRE
VILTEPSO injection Long-Term Trial Data to be Presented at PPMD 2021 Conference
12 May 2021 //
PRNEWSWIRE
NS Pharma`s VILTEPSO® (viltolarsen) Receives Permanent J-code
01 Apr 2021 //
PRNEWSWIRE
VILTEPSO™ (viltolarsen) injection Now Commercially Available in the U.S.
19 Aug 2020 //
PRNEWSWIRE
NS Pharma Announces Publication of Clinical Trial Data for Viltolarsen
26 May 2020 //
PR NEWSWIRE
